Jefferies analyst Akash Tewari raised the firm’s price target on Regeneron (REGN) to $940 from $925 and keeps a Buy rating on the shares. Following Dupixent’s recent "strong" COPD data, the firm says its now "closely tracking" the company’s Eylea intellectual property trial versus Viatris’ (VTRS) Mylan, which has a trial in June, and "particularly the imminent markman decision." Claim construction is "key here," argues the firm, which says a favorable ruling in the ongoing West Virginia District Court Case may delay biosimilar entry and may allow Regeneron to protect Eylea to 2024-plus.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on REGN:
- Kodiak Q4 update had ‘a few nice surprises,’ says Capital One
- Regeneron announces EC approved Libtayo in combination with chemotherapy
- Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
- Regeneron price target raised to $650 from $605 at BofA
- Regeneron resumed with a Buy at Erste Group